A sentinel lymph node biopsy is a specialised diagnostic procedure used to determine if melanoma cells have spread from the primary skin site to the regional lymphatic system. While not every patient with a skin cancer diagnosis requires this test, it is a key component of the staging process for those with specific risk factors. By identifying microscopic spread that is not yet visible on a scan or detectable during a physical examination, the medical team can more accurately define the stage of the disease and plan the most appropriate subsequent treatments.
What We’ll Discuss in This Article
- The primary role of Breslow thickness in determining eligibility.
- Specific risk factors that warrant a biopsy for thinner melanomas.
- Why the procedure is restricted to patients with clinically clear nodes.
- The clinical benefits of identifying microscopic stage 3 disease.
- How the biopsy results influence the use of modern immunotherapy.
- Situations where a sentinel lymph node biopsy is not recommended.
Determining eligibility based on Breslow thickness
The most significant factor used by UK clinicians to decide if a sentinel lymph node biopsy is appropriate is the measured depth of the primary melanoma. According to current standards, the procedure is strongly considered for any patient whose melanoma has a Breslow thickness of more than one millimetre. At this depth, the statistical risk of the cancer cells reaching the lymphatic channels increases sufficiently to justify the surgical investigation. Healthcare professionals in the UK follow established protocols to offer a sentinel lymph node biopsy to patients with stage 1B to 2C melanoma to ensure accurate staging.
Risk factors influencing decisions for thinner melanomas
For melanomas that are between 0.8 millimetres and 1.0 millimetre thick, the decision to recommend a biopsy depends on the presence of additional high-risk features. These features include ulceration, which is when the skin over the melanoma has broken down, and a high mitotic rate, which indicates that the cancer cells are dividing rapidly. If a melanoma in this thickness range displays any of these characteristics, it is often treated with the same level of priority as a thicker lesion. NICE guidelines recommend considering a sentinel lymph node biopsy for melanomas between 0.8 and 1.0 millimetre if ulceration or lymphovascular invasion is identified by the pathologist.
Why the biopsy is limited to clinically node-negative patients
A sentinel lymph node biopsy is specifically designed to find microscopic spread that cannot be felt during a physical examination or seen on a standard scan. If a patient already has a palpable or swollen lymph node that the doctor can feel, this procedure is generally not recommended. In such cases, the medical team will instead perform a fine-needle aspiration or an ultrasound-guided biopsy to confirm the presence of cancer in the visible lump. The sentinel biopsy is most effective as a staging tool for patients who appear to have clear lymph nodes but require further investigation to be certain.
The role of the procedure in treatment planning
Identifying microscopic spread through a sentinel lymph node biopsy is essential for accessing modern systemic treatments such as adjuvant immunotherapy or targeted therapy. If the biopsy reveals that melanoma cells have reached the sentinel node, the patient’s diagnosis is updated to stage 3. This change in stage allows the multidisciplinary team to offer medications that work throughout the body to reduce the risk of the cancer returning elsewhere. Without the information provided by the biopsy, these preventative treatments might not be authorised, as their use is strictly tied to the confirmed stage of the disease.
Situations where a biopsy is not recommended
There are several scenarios where a sentinel lymph node biopsy is typically omitted from the clinical pathway. This includes patients with very thin melanomas, known as stage 1A, which are less than 0.8 millimetres thick and do not show any high-risk features. For these early-stage lesions, the risk of lymphatic spread is so low that the potential complications of surgery are thought to outweigh the diagnostic benefits. Additionally, the procedure may not be recommended for individuals with significant underlying health conditions that make a general anaesthetic unsafe or for those where the primary melanoma is located in an area where lymphatic drainage is highly unpredictable.
Integrating the biopsy into surgical care
The sentinel lymph node biopsy is usually performed at the same time as the wide local excision, which is the surgery to remove more skin from around the original melanoma site. This coordinated approach means the patient only needs to undergo a single period of anaesthesia and one recovery phase. Before the surgery, a specialised scan called a lymphoscintigram is used to map the exact location of the sentinel nodes. This ensures the surgeon can identify the correct glands with high precision, minimising the amount of tissue that needs to be removed and reducing the risk of postoperative complications.
Conclusion
A sentinel lymph node biopsy is recommended for patients with a melanoma thickness of more than one millimetre, or for those with thinner lesions that display high-risk features like ulceration. The procedure serves as a critical staging tool that can identify microscopic spread, helping to guide decisions regarding further surgical margins and the use of preventative drug therapies. While it is an optional part of the clinical pathway, it provides the most accurate assessment of whether the cancer has moved beyond its original site. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Is a sentinel lymph node biopsy a cure for melanoma?
No, the procedure is a diagnostic test used for staging rather than a treatment to cure the disease, though it helps doctors decide which treatments are needed.
Will I have the biopsy if my melanoma is only 0.5 millimetres thick?
Usually no, as melanomas thinner than 0.8 millimetres have a very low risk of spread and do not typically meet the criteria for this procedure.
What happens if I decide not to have the biopsy?
If you choose not to have the biopsy, your stage will be based on the skin lesion alone, and you will continue to have regular physical check-ups to monitor your lymph nodes.
Is the procedure done under local or general anaesthetic?
In the UK, a sentinel lymph node biopsy is almost always performed under a general anaesthetic because it involves finding and removing glands deeper in the tissue.
Can the biopsy be done after the wide local excision?
While it is technically possible, it is much harder to identify the correct sentinel nodes after the local skin architecture has been altered by a previous wide excision.
How many lymph nodes are usually removed?
The surgeon typically removes only the sentinel nodes, which is usually one to three glands, rather than removing all the nodes in that area.
Does a positive result mean I need more surgery?
In the past, a positive result often led to the removal of all remaining nodes, but current practice often involves using drug treatments or close ultrasound monitoring instead.
Authority Snapshot (E-E-A-T)
This article is designed to provide clear and factual information regarding skin health for the general public. The content is written by the Medical Content Team and has been reviewed by Dr. Stefan Petrov. He is a UK-trained physician with an MBBS and postgraduate certifications including Basic Life Support (BLS), Advanced Cardiac Life Support (ACLS), and the UK Medical Licensing Assessment (PLAB 1 & 2). He has hands-on experience in general medicine, surgery, anaesthesia, ophthalmology, and emergency care. Dr. Petrov has worked in both hospital wards and intensive care units, performing diagnostic and therapeutic procedures, and has contributed to medical education by creating patient-focused health content and teaching clinical skills to junior doctors.
